Saturday, July 31, 2021

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial


https://ift.tt/3gXIxqG via /r/science https://ift.tt/3fj8P5t

No comments:

Post a Comment

Popular Posts